The race for a COVID-19 vaccine: where are we up to?
- PMID: 34937492
- DOI: 10.1080/14760584.2022.2021074
The race for a COVID-19 vaccine: where are we up to?
Abstract
Introduction: A novel strain of coronavirus, SARS-CoV-2, has triggered a global pandemic of coronavirus disease (COVID-19) in late 2019. In January 2020, the WHO declared this pandemic a public health emergency. This pandemic has already caused over 5.3 million deaths from more than 272 million infections. The development of a successful vaccine is an urgent global priority to halt the spread of SARS-CoV-2 and prevent further fatalities. Researchers are fast-tracking this process, and there have already been significant developments in preclinical and clinical phases in a relatively short period of time. Some vaccines have been approved either for emergency use or mass application in recent months.
Areas covered: Herein, we provide a general understanding of the fast-tracked clinical trial procedures and highlight recent successes in preclinical and clinical trials to generate a clearer picture of the progress of COVID-19 vaccine development.
Expert opinion: A good number of vaccines have been rolled out within a short period a feat unprecedented in medical history. However, the emergence of new variants over time has appeared as a new threat, and the number of infections and casualties is still on the rise and this is going to be an ongoing battle.
Keywords: COVID-19; clinical; fast track; pandemic; preclinical; vaccine.
Similar articles
-
Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world.Front Immunol. 2022 Oct 3;13:961198. doi: 10.3389/fimmu.2022.961198. eCollection 2022. Front Immunol. 2022. PMID: 36263030 Free PMC article. Review.
-
Clinical development and approval of COVID-19 vaccines.Expert Rev Vaccines. 2022 May;21(5):609-619. doi: 10.1080/14760584.2022.2042257. Epub 2022 Mar 14. Expert Rev Vaccines. 2022. PMID: 35157542 Free PMC article.
-
Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.Cells. 2021 Oct 29;10(11):2949. doi: 10.3390/cells10112949. Cells. 2021. PMID: 34831172 Free PMC article. Review.
-
Super-rapid race for saving lives by developing COVID-19 vaccines.J Integr Bioinform. 2021 Mar 25;18(1):27-43. doi: 10.1515/jib-2021-0002. J Integr Bioinform. 2021. PMID: 33761582 Free PMC article. Review.
-
The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.Arch Razi Inst. 2021 Mar;76(1):1-6. doi: 10.22092/ari.2021.353761.1612. Epub 2021 Mar 1. Arch Razi Inst. 2021. PMID: 33818952 Free PMC article.
Cited by
-
Dose Intervals and Time since Final Dose on Changes in Metabolic Indices after COVID-19 Vaccination.Vaccines (Basel). 2023 Nov 23;11(12):1746. doi: 10.3390/vaccines11121746. Vaccines (Basel). 2023. PMID: 38140151 Free PMC article.
-
Intraduodenal Delivery of Exosome-Loaded SARS-CoV-2 RBD mRNA Induces a Neutralizing Antibody Response in Mice.Vaccines (Basel). 2023 Mar 16;11(3):673. doi: 10.3390/vaccines11030673. Vaccines (Basel). 2023. PMID: 36992256 Free PMC article.
-
Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world.Front Immunol. 2022 Oct 3;13:961198. doi: 10.3389/fimmu.2022.961198. eCollection 2022. Front Immunol. 2022. PMID: 36263030 Free PMC article. Review.
-
Computational and Enzymatic Studies of Sartans in SARS-CoV-2 Spike RBD-ACE2 Binding: The Role of Tetrazole and Perspectives as Antihypertensive and COVID-19 Therapeutics.Int J Mol Sci. 2023 May 8;24(9):8454. doi: 10.3390/ijms24098454. Int J Mol Sci. 2023. PMID: 37176159 Free PMC article.
-
BCG and SARS-CoV-2-What Have We Learned?Vaccines (Basel). 2022 Sep 30;10(10):1641. doi: 10.3390/vaccines10101641. Vaccines (Basel). 2022. PMID: 36298506 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous